according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone (0.05%) Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1688537-00015 Date of first issue: 18.05.2017

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Betamethasone (0.05%) Ointment Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Pharmaceutical

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.

30 Hudson Street, 33nd floor

07302 Jersey City, New Jersey, U.S.A

Telephone : +1-551-430-6000

E-mail address of person

responsible for the SDS

: EHSSTEWARD@organon.com

1.4 Emergency telephone number

+1-215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1B H36

Specific target organ toxicity - repeated

exposure, Category 1

Long-term (chronic) aquatic hazard, Cat-

egory 1

H360D: May damage the unborn child.

H372: Causes damage to organs through pro-

longed or repeated exposure.

H410: Very toxic to aquatic life with long lasting

effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms



*

Signal word : Danger

Hazard statements : H360D May damage the unborn child.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone (0.05%) Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1688537-00015 Date of first issue: 18.05.2017

H372 Causes damage to organs through prolonged or re-

peated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements

Prevention:

P201 Obtain special instructions before use.
P264 Wash skin thoroughly after handling.
P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P391 Collect spillage.

Hazardous components which must be listed on the label:

betamethasone

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

| Chemical name | CAS-No. EC-No. Index-No. Registration number | Classification | Concentration (% w/w) |
|---------------|---|--|--------------------------|
| betamethasone | 378-44-9 206-825-4 | Acute Tox. 2; H330 Repr. 1B; H360D STOT RE 1; H372 (Pituitary gland, Immune system, muscle, thymus gland, Blood, Ad- renal gland) Aquatic Chronic 1: | >= 0,025 - < 0,1 |

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone (0.05%) Ointment Formulation

| Version 5.0 | Revision Date: 06.04.2024 | SDS Number: 1688537-00015 | Date of last issue: 30.09.2023 Date of first issue: 18.05.2017 |
|----------------|---------------------------|------------------------------|--|
| | | | M-Factor (Chronic aquatic toxicity): 1.000 specific concentration limit STOT RE 1; H372 >= 0,01 % Repr. 1B; H360D >= 0,01 % |

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : May damage the unborn child.

Causes damage to organs through prolonged or repeated

exposure.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone (0.05%) Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1688537-00015 Date of first issue: 18.05.2017

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Vapours may form explosive mixtures with air.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone (0.05%) Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1688537-00015 Date of first issue: 18.05.2017

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust, fume, gas, mist, vapours or spray.

Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national

regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone (0.05%) Ointment Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 1688537-00015
 Date of first issue: 18.05.2017

Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

| Components | CAS-No. | Value type (Form of exposure) | Control parameters | Basis |
|------------------|---------------------------|-------------------------------|---------------------------|-------------------------|
| Petrolatum | 8009-03-8 | TWA (Vapour) | 50 mg/m3 | FOR-2011- 12-06-1358 |
| | | TWA (Mist and particles) | 1 mg/m3 | FOR-2011- 12-06-1358 |
| Propylene glycol | 57-55-6 | TWA | 25 ppm 79 mg/m3 | FOR-2011- 12-06-1358 |
| betamethasone | 378-44-9 | TWA | 1 μg/m3 (OEB 4) | Internal |
| | Further information: Skin | | | |
| | | Wipe limit | 10 μg/100 cm ² | Internal |

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

| (, (, (, (, (, (, (, (, (, (, (, (, (, (, | | | | |
|---|-----------|-----------------|----------------------|-----------|
| Substance name | End Use | Exposure routes | Potential health ef- | Value |
| | | | fects | |
| Propylene glycol | Workers | Inhalation | Long-term local ef- | 10 mg/m3 |
| | | | fects | |
| | Workers | Inhalation | Long-term systemic | 168 mg/m3 |
| | | | effects | |
| | Consumers | Inhalation | Long-term local ef- | 10 mg/m3 |
| | | | fects | |
| | Consumers | Inhalation | Long-term systemic | 50 mg/m3 |
| | | | effects | |

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

| Substance name | Environmental Compartment | Value |
|------------------|----------------------------|---------------------------------|
| Petrolatum | Oral (Secondary Poisoning) | 9,33 mg/kg food |
| Propylene glycol | Fresh water | 260 mg/l |
| | Freshwater - intermittent | 183 mg/l |
| | Marine water | 26 mg/l |
| | Sewage treatment plant | 20000 mg/l |
| | Fresh water sediment | 572 mg/kg dry weight (d.w.) |
| | Marine sediment | 57,2 mg/kg dry weight (d.w.) |
| | Soil | 50 mg/kg dry weight (d.w.) |

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone (0.05%) Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1688537-00015 Date of first issue: 18.05.2017

8.2 Exposure controls

Engineering measures

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to NS EN 143

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : ointment

Colour : white to off-white

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

Flammability (solid, gas) : Not classified as a flammability hazard

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone (0.05%) Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1688537-00015 Date of first issue: 18.05.2017

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : > 93,3 °C

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : Not applicable

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Vapour pressure : No data available

Relative density : No data available

Density : No data available

Relative vapour density : Not applicable

Particle characteristics

Particle size : Not applicable

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : Not applicable

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone (0.05%) Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1688537-00015 Date of first issue: 18.05.2017

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Vapours may form explosive mixture with air.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Skin contact exposure Ingestion

Eye contact

Acute toxicity

Not classified based on available information.

Components:

betamethasone:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

LD50 (Mouse): > 4.500 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0,4 mg/l

Exposure time: 4 h

Skin corrosion/irritation

Not classified based on available information.

Components:

betamethasone:

Species : Rabbit

Result : Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

betamethasone:

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone (0.05%) Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1688537-00015 Date of first issue: 18.05.2017

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

betamethasone:

Exposure routes : Dermal
Species : Guinea pig
Result : Weak sensitizer

Germ cell mutagenicity

Not classified based on available information.

Components:

betamethasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse Application Route: Oral Result: equivocal

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

May damage the unborn child.

Components:

betamethasone:

Effects on foetal develop- : Species: Rabbit

ment Application Route: Intramuscular

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone (0.05%) Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1688537-00015 Date of first issue: 18.05.2017

Developmental Toxicity: LOAEL: 0,05 mg/kg body weight

Result: Fetotoxicity, Malformations were observed.

Species: Rat

Application Route: Subcutaneous

Developmental Toxicity: LOAEL: 0,42 mg/kg body weight

Result: Malformations were observed.

Species: Mouse

Application Route: Intramuscular

Developmental Toxicity: LOAEL: 1 mg/kg body weight

Result: Malformations were observed.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Components:

betamethasone:

Target Organs : Pituitary gland, Immune system, muscle, thymus gland, Blood,

Adrenal gland

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

betamethasone:

Species : Rabbit
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 10 - 30 d

Target Organs : Pituitary gland, Immune system, muscle

Species : Rat
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

Species : Mouse
LOAEL : 0.1 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone (0.05%) Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 06.04.2024 1688537-00015 Date of first issue: 18.05.2017 5.0

Species Dog

LOAEL 0,05 mg/kg Application Route Oral Exposure time

Target Organs Blood, thymus gland, Adrenal gland

28 d

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment The substance/mixture does not contain components consid-

> ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

Components:

betamethasone:

Target Organs: Adrenal gland Inhalation

Skin contact Symptoms: Redness, pruritis, Irritation

SECTION 12: Ecological information

12.1 Toxicity

Components:

betamethasone:

Toxicity to daphnia and other : EC50 (Americamysis): > 50 mg/l

aquatic invertebrates Exposure time: 96 h

Toxicity to algae/aquatic EC50 (Pseudokirchneriella subcapitata (green algae)): > 34

plants mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 34

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

NOEC: 0,052 mg/l Exposure time: 32 d

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone (0.05%) Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1688537-00015 Date of first issue: 18.05.2017

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

NOEC: 0,07 µg/l Exposure time: 219 d

Species: Oryzias latipes (Japanese medaka)

Method: OECD Test Guideline 229

Toxicity to daphnia and other : aquatic invertebrates (Chron-

and other : NOEC: 8 mg/l es (Chron- Exposure time: 21 d

ic toxicity)

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

M-Factor (Chronic aquatic :

toxicity)

1.000

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

Components:

betamethasone:

Partition coefficient: n-

: log Pow: 2,11

octanol/water

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone (0.05%) Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1688537-00015 Date of first issue: 18.05.2017

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : UN 3077
ADR : UN 3077
RID : UN 3077
IMDG : UN 3077
IATA : UN 3077

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone)

IATA : Environmentally hazardous substance, solid, n.o.s.

(betamethasone)

14.3 Transport hazard class(es)

Class Subsidiary risks

ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9

14.4 Packing group

ADN

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone (0.05%) Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1688537-00015 Date of first issue: 18.05.2017

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

ADR

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

IMDG

Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 956

aircraft)

Packing instruction (LQ) : Y956 Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen- : 956

ger aircraft)

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone (0.05%) Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 06.04.2024 1688537-00015 Date of first issue: 18.05.2017 5.0

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

Conditions of restriction for the following entries should be considered: Number on list 75

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or

If you intend to use this product as tattoo ink, please contact your ven-

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation

(Annex XIV)

Regulation (EC) No 1005/2009 on substances that de-

plete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollu-

tants (recast)

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import

Not applicable

Not applicable

Not applicable

Not applicable Not applicable

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Quantity 1 Quantity 2 E1 **ENVIRONMENTAL** 100 t 200 t **HAZARDS**

Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone (0.05%) Ointment Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 1688537-00015
 Date of first issue: 18.05.2017

children and young people.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H330 : Fatal if inhaled.

H360D : May damage the unborn child.

H372 : Causes damage to organs through prolonged or repeated

exposure.

H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Chronic : Long-term (chronic) aquatic hazard

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

FOR-2011-12-06-1358 : Norway. Occupational Exposure limits

FOR-2011-12-06-1358 / : Long term exposure limit

TWA

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified;

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone (0.05%) Ointment Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 1688537-00015
 Date of first issue: 18.05.2017

NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data
Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

Repr. 1B H360D Calculation method STOT RE 1 H372 Calculation method Aquatic Chronic 1 H410 Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN